Advanz Zeroes In On Innovative Assets And M&A
Business Has Increased In Value To Around €670m
Executive Summary
Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.
You may also be interested in...
Burden Departs Advanz As Intercept Deal Completes
As Advanz completes its deal to acquire Intercept’s ex-US business, the company has confirmed a management change that has seen chief commercial officer Paul Burden leave the company, with the appointment of two new regional CCOs.
Generics Bulletin Podcast – GenBioPro v. West Virginia: The Future Of Mifepristone In America, With Professor Greer Donley
Generics Bulletin spoke to University of Pittsburgh School of Law professor Greer Donley, a specialist in reproductive law, about generic mifepristone manufacturer GenBioPro’s lawsuit challenging West Virginia’s state-level restrictions on medical abortion access and its potential wider relevance for the industry.
Instead Of VC, Try Philanthropy: Inside Medical Research Charity LifeArc
In Vivo reporter Chloe Kent caught up with Life Arc CEO Melanie Lee to discuss the power of philanthropy in early-stage biopharma funding.